Madeline R Sponholtz, Patrick O Byrne, Alison G Lee, Ajit R Ramamohan, Jory A Goldsmith, Ryan S McCool, Ling Zhou, Nicole V Johnson, Ching-Lin Hsieh, Megan Connors, Krithika P Karthigeyan, Chelsea M Crooks, Adelaide S Fuller, John D Campbell, Sallie R Permar, Jennifer A Maynard, Dong Yu, Matthew J Bottomley, Jason S McLellan
{"title":"基于结构设计的可溶性人类巨细胞病毒糖蛋白 B 抗原,以类似预融合的构象稳定下来。","authors":"Madeline R Sponholtz, Patrick O Byrne, Alison G Lee, Ajit R Ramamohan, Jory A Goldsmith, Ryan S McCool, Ling Zhou, Nicole V Johnson, Ching-Lin Hsieh, Megan Connors, Krithika P Karthigeyan, Chelsea M Crooks, Adelaide S Fuller, John D Campbell, Sallie R Permar, Jennifer A Maynard, Dong Yu, Matthew J Bottomley, Jason S McLellan","doi":"10.1073/pnas.2404250121","DOIUrl":null,"url":null,"abstract":"<p><p>Human cytomegalovirus (HCMV) glycoprotein B (gB) is a class III membrane fusion protein required for viral entry. HCMV vaccine candidates containing gB have demonstrated moderate clinical efficacy, but no HCMV vaccine has been approved. Here, we used structure-based design to identify and characterize amino acid substitutions that stabilize gB in its metastable prefusion conformation. One variant containing two engineered interprotomer disulfide bonds and two cavity-filling substitutions (gB-C7), displayed increased expression and thermostability. A 2.8 Å resolution cryoelectron microscopy structure shows that gB-C7 adopts a prefusion-like conformation, revealing additional structural elements at the membrane-distal apex. Unlike previous observations for several class I viral fusion proteins, mice immunized with postfusion or prefusion-stabilized forms of soluble gB protein displayed similar neutralizing antibody titers, here specifically against an HCMV laboratory strain on fibroblasts. Collectively, these results identify initial strategies to stabilize class III viral fusion proteins and provide tools to probe gB-directed antibody responses.</p>","PeriodicalId":20548,"journal":{"name":"Proceedings of the National Academy of Sciences of the United States of America","volume":null,"pages":null},"PeriodicalIF":9.4000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406251/pdf/","citationCount":"0","resultStr":"{\"title\":\"Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation.\",\"authors\":\"Madeline R Sponholtz, Patrick O Byrne, Alison G Lee, Ajit R Ramamohan, Jory A Goldsmith, Ryan S McCool, Ling Zhou, Nicole V Johnson, Ching-Lin Hsieh, Megan Connors, Krithika P Karthigeyan, Chelsea M Crooks, Adelaide S Fuller, John D Campbell, Sallie R Permar, Jennifer A Maynard, Dong Yu, Matthew J Bottomley, Jason S McLellan\",\"doi\":\"10.1073/pnas.2404250121\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Human cytomegalovirus (HCMV) glycoprotein B (gB) is a class III membrane fusion protein required for viral entry. HCMV vaccine candidates containing gB have demonstrated moderate clinical efficacy, but no HCMV vaccine has been approved. Here, we used structure-based design to identify and characterize amino acid substitutions that stabilize gB in its metastable prefusion conformation. One variant containing two engineered interprotomer disulfide bonds and two cavity-filling substitutions (gB-C7), displayed increased expression and thermostability. A 2.8 Å resolution cryoelectron microscopy structure shows that gB-C7 adopts a prefusion-like conformation, revealing additional structural elements at the membrane-distal apex. Unlike previous observations for several class I viral fusion proteins, mice immunized with postfusion or prefusion-stabilized forms of soluble gB protein displayed similar neutralizing antibody titers, here specifically against an HCMV laboratory strain on fibroblasts. Collectively, these results identify initial strategies to stabilize class III viral fusion proteins and provide tools to probe gB-directed antibody responses.</p>\",\"PeriodicalId\":20548,\"journal\":{\"name\":\"Proceedings of the National Academy of Sciences of the United States of America\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406251/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of the National Academy of Sciences of the United States of America\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1073/pnas.2404250121\",\"RegionNum\":1,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the National Academy of Sciences of the United States of America","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1073/pnas.2404250121","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
人巨细胞病毒(HCMV)糖蛋白 B(gB)是病毒进入人体所需的第三类膜融合蛋白。含有 gB 的 HCMV 候选疫苗已显示出适度的临床疗效,但目前还没有 HCMV 疫苗获得批准。在这里,我们利用基于结构的设计来确定和描述能使 gB 稳定在其可转移的预融合构象中的氨基酸取代。其中一个变体包含两个原体间二硫键和两个空腔填充取代(gB-C7),其表达和热稳定性均有所提高。2.8 Å 分辨率的冷冻电镜结构显示,gB-C7 采用了类似预融合的构象,揭示了膜远端顶点的附加结构元素。与之前对几种 I 类病毒融合蛋白的观察结果不同的是,用融合后或融合前稳定形式的可溶性 gB 蛋白免疫小鼠,显示出相似的中和抗体滴度,在此特别针对成纤维细胞上的 HCMV 实验室株。总之,这些结果确定了稳定 III 类病毒融合蛋白的初步策略,并为探究 gB 引导的抗体反应提供了工具。
Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation.
Human cytomegalovirus (HCMV) glycoprotein B (gB) is a class III membrane fusion protein required for viral entry. HCMV vaccine candidates containing gB have demonstrated moderate clinical efficacy, but no HCMV vaccine has been approved. Here, we used structure-based design to identify and characterize amino acid substitutions that stabilize gB in its metastable prefusion conformation. One variant containing two engineered interprotomer disulfide bonds and two cavity-filling substitutions (gB-C7), displayed increased expression and thermostability. A 2.8 Å resolution cryoelectron microscopy structure shows that gB-C7 adopts a prefusion-like conformation, revealing additional structural elements at the membrane-distal apex. Unlike previous observations for several class I viral fusion proteins, mice immunized with postfusion or prefusion-stabilized forms of soluble gB protein displayed similar neutralizing antibody titers, here specifically against an HCMV laboratory strain on fibroblasts. Collectively, these results identify initial strategies to stabilize class III viral fusion proteins and provide tools to probe gB-directed antibody responses.
期刊介绍:
The Proceedings of the National Academy of Sciences (PNAS), a peer-reviewed journal of the National Academy of Sciences (NAS), serves as an authoritative source for high-impact, original research across the biological, physical, and social sciences. With a global scope, the journal welcomes submissions from researchers worldwide, making it an inclusive platform for advancing scientific knowledge.